Seres Therapeutics Inc (MCRB)
0.8166
+0.02
(+2.70%)
USD |
NASDAQ |
Nov 05, 16:00
0.8166
0.00 (0.00%)
After-Hours: 18:25
Seres Therapeutics Net Income (Quarterly): -32.87M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | -32.87M |
| March 31, 2024 | -40.13M |
| December 31, 2023 | -41.25M |
| September 30, 2023 | -47.85M |
| June 30, 2023 | 46.55M |
| March 31, 2023 | -71.17M |
| December 31, 2022 | -68.80M |
| September 30, 2022 | -60.00M |
| June 30, 2022 | -64.74M |
| March 31, 2022 | -56.62M |
| December 31, 2021 | -50.00M |
| September 30, 2021 | 68.22M |
| June 30, 2021 | -48.33M |
| March 31, 2021 | -35.46M |
| December 31, 2020 | -18.25M |
| September 30, 2020 | -30.28M |
| June 30, 2020 | -20.71M |
| March 31, 2020 | -19.88M |
| December 31, 2019 | -18.78M |
| September 30, 2019 | -16.41M |
| June 30, 2019 | -10.76M |
| Date | Value |
|---|---|
| March 31, 2019 | -24.33M |
| December 31, 2018 | -21.29M |
| September 30, 2018 | -21.95M |
| June 30, 2018 | -27.79M |
| March 31, 2018 | -27.92M |
| December 31, 2017 | -28.95M |
| September 30, 2017 | -6.935M |
| June 30, 2017 | -28.02M |
| March 31, 2017 | -25.47M |
| December 31, 2016 | -25.28M |
| September 30, 2016 | -18.69M |
| June 30, 2016 | -27.91M |
| March 31, 2016 | -19.70M |
| December 31, 2015 | -19.63M |
| September 30, 2015 | -14.62M |
| June 30, 2015 | -12.56M |
| March 31, 2015 | -7.971M |
| December 31, 2014 | -8.182M |
| September 30, 2014 | -4.161M |
| June 30, 2014 | -2.677M |
| March 31, 2014 | -1.689M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-71.17M
Minimum
Mar 2023
68.22M
Maximum
Sep 2021
-32.12M
Average
-40.13M
Median
Mar 2024
Net Income (Quarterly) Benchmarks
| Chimerix Inc | -20.68M |
| Cellectar Biosciences Inc | -0.9194M |
| Marinus Pharmaceuticals Inc | -35.83M |
| Jaguar Health Inc | -9.492M |
| PDS Biotechnology Corp | -8.328M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 31.34M |
| EPS Diluted (Quarterly) | -0.22 |
| Enterprise Value | 151.90M |
| Earnings Yield | -144.5% |
| Normalized Earnings Yield | -110.21 |